Effects of a Family-centered Early Palliative Care Intervention on the Mental Health and Quality of Life in Patients With Advanced Cancer and Their Caregivers.

Am J Clin OncolFeb 13, 2026 (epub)

Congming Bu, Jing Wang, Feng Gu et al.

✦ AI-curated · Sources linked

In 30 seconds

This remote randomized controlled trial evaluated family-centered early palliative care in Chinese patients with advanced lung, breast, or colon cancer and their caregivers. Patients and caregivers were randomized as pairs to four weeks of health education alone or health education plus four weeks of early palliative care. At both the immediate post-intervention assessment and one-month follow-up, patients receiving the intervention had higher resilience, benefit discovery, and quality of life, and lower anxiety and depression than controls (P <0.01). Group, time, and role interactions were also reported for anxiety, depression, and resilience.

Key findings

  • At both post-intervention assessments, intervention-group patients had higher resilience, benefit discovery, and quality of life than controls (P <0.01).
  • Intervention-group patients had lower anxiety and depression than controls at both post-intervention assessments (P <0.01).
  • Group-by-time-by-role interactions were reported for anxiety, depression, and resilience (P <0.01), with differences between patients and caregivers.

Why it matters

Advanced cancer affects patients and caregivers together, and this trial assessed outcomes in both members of the pair. Its findings suggest that adding early palliative care to health education may support emotional well-being and quality of life, while the reported role differences indicate that outcomes may not be identical for patients and caregivers.

What to keep in mind

The abstract reports outcomes only through one month after the intervention, so longer-term effects are not established.

Source

Published in Am J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.